Inrebic

Showing 1 posts of 1 posts found.

celgene_1_02

Celgene’s Inrebic becomes second FDA-approved therapy for rare bone marrow disorder

August 19, 2019
Sales and Marketing Cancer, Cerlgene, FDA, Inrebic, pharma, rare disease

Celgene is celebrating the approval in the US of its Janus kinase (JAK) 2 inhibitor Inrebic (fedratinib) in the treatment …

Latest content